6:10 PM
Sep 12, 2012
 |  BC Extra  |  Clinical News

Oncolytics off on Phase III update

Shares of Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) fell on Wednesday after the company amended the Phase III REO 018 trial of IV Reolysin in combination with carboplatin and paclitaxel vs. chemotherapy alone in patients with head and neck cancer. The company said the changes could delay the report of progression-free survival data by at least three...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >